董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| James W. Young | 男 | Non-executive Chairman | 72 | 8.17万(USD) | 未持股 | 2017-04-01 |
| Daniel N. Swisher, Jr. | 男 | Director, Chief Executive Officer and President | 54 | 154.43万(USD) | 未持股 | 2017-04-01 |
| Matthew K. Fust | 男 | 董事 | 52 | 8.92万(USD) | 未持股 | 2017-04-01 |
| Homer L. Pearce | 男 | 董事 | 64 | 6.92万(USD) | 未持股 | 2017-04-01 |
| Dayton Misfeldt | 男 | 董事 | 43 | 8.17万(USD) | 未持股 | 2017-04-01 |
| Steven B. Ketchum | 男 | 董事 | 52 | 6.17万(USD) | 未持股 | 2017-04-01 |
| David C. Stump | 男 | 董事 | 67 | 7.17万(USD) | 未持股 | 2017-04-01 |
| Geoffrey M. Parker | 男 | 董事 | 52 | 6.98万(USD) | 未持股 | 2017-04-01 |
| Steve R. Carchedi | 男 | 董事 | 55 | 6.92万(USD) | 未持股 | 2017-04-01 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Daniel N. Swisher, Jr. | 男 | Director, Chief Executive Officer and President | 54 | 154.43万(USD) | 未持股 | 2017-04-01 |
| Eric H. Bjerkholt | 男 | Executive Vice President, Corporate Development and Finance and Chief Financial Officer | 57 | 86.97万(USD) | 未持股 | 2017-04-01 |
董事简历
中英对照 | 中文 | 英文- James W. Young
James W. Young, Ph.D.,从2003年12月到2009年4月,他担任我们非执行董事长.2009年4月以来,他担任我们非执行董事长.从2000年5月到2003年11月，他担任我们的首席执行官。2006年4月,他加入 5AM Ventures(风险资本公司)并担任其投资合伙人.从1995年9月到2000年3月,他担任 ALZA Corporation(制药公司)的副总裁负责研究、高级副总裁负责研发和部门副总裁。从1992年9月到1995年8月，他担任Affymax, N.V.（生物制药公司）的高级副总裁负责业务拓展和总裁负责要务部门。从1987年9月到1992年8月，他担任Sepracor Inc.（生物制药公司）的高级副总裁负责业务拓展和高级副总裁和总经理负责药品部门。从2000年到2005年7月，他曾担任Corixa Corporation（生物制药公司）的董事。他获得福特汉姆大学(Fordham University)的化学学士学位和康奈尔大学（ Cornell University ）的有机化学博士学位.
James W. Young served as Executive Chairman of our Board from December 2003 to April 2009 and has served as non-executive Chairman of our Board since April 2009. From May 2000 to November 2003 Dr. Young served as our Chief Executive Officer. In April 2006 he joined 5AM Ventures, a venture capital firm, as a Venture Partner. From September 1995 to March 2000 Dr. Young served as Vice President of Research, as Senior Vice President, Research and Development, and as Group Vice President at ALZA Corporation, a pharmaceutical company. From September 1992 to August 1995 Dr. Young served as Senior Vice President for Business Development and as President of the Pharmaceuticals Division of Affymax, N.V., a biopharmaceutical company. From September 1987 to August 1992 he served as Senior Vice President for Business Development and as Senior Vice President and General Manager of the Pharmaceuticals Division at Sepracor Inc., a pharmaceutical company. Dr. Young holds a B.S. in Chemistry from Fordham University and a Ph.D. in Organic Chemistry from Cornell University.- James W. Young, Ph.D.,从2003年12月到2009年4月,他担任我们非执行董事长.2009年4月以来,他担任我们非执行董事长.从2000年5月到2003年11月，他担任我们的首席执行官。2006年4月,他加入 5AM Ventures(风险资本公司)并担任其投资合伙人.从1995年9月到2000年3月,他担任 ALZA Corporation(制药公司)的副总裁负责研究、高级副总裁负责研发和部门副总裁。从1992年9月到1995年8月，他担任Affymax, N.V.（生物制药公司）的高级副总裁负责业务拓展和总裁负责要务部门。从1987年9月到1992年8月，他担任Sepracor Inc.（生物制药公司）的高级副总裁负责业务拓展和高级副总裁和总经理负责药品部门。从2000年到2005年7月，他曾担任Corixa Corporation（生物制药公司）的董事。他获得福特汉姆大学(Fordham University)的化学学士学位和康奈尔大学（ Cornell University ）的有机化学博士学位.
- James W. Young served as Executive Chairman of our Board from December 2003 to April 2009 and has served as non-executive Chairman of our Board since April 2009. From May 2000 to November 2003 Dr. Young served as our Chief Executive Officer. In April 2006 he joined 5AM Ventures, a venture capital firm, as a Venture Partner. From September 1995 to March 2000 Dr. Young served as Vice President of Research, as Senior Vice President, Research and Development, and as Group Vice President at ALZA Corporation, a pharmaceutical company. From September 1992 to August 1995 Dr. Young served as Senior Vice President for Business Development and as President of the Pharmaceuticals Division of Affymax, N.V., a biopharmaceutical company. From September 1987 to August 1992 he served as Senior Vice President for Business Development and as Senior Vice President and General Manager of the Pharmaceuticals Division at Sepracor Inc., a pharmaceutical company. Dr. Young holds a B.S. in Chemistry from Fordham University and a Ph.D. in Organic Chemistry from Cornell University.
- Daniel N. Swisher, Jr.
Daniel N. Swisher, Jr.，2004年1月以来，他担任我们呢首席执行官以及我们董事会成员。2004年1月以来，他也担任我们呢总裁。从2001年12月到2003年12月，他担任我们的首席商务官和首席财务官。从1992年6月到2001年9月，他担任各种管理职务，包括ALZA Corporation的高级副总裁负责销售和市场营销。他担任Cerus Corporation（生物制药公司）的董事会非执行主席。他持有耶鲁大学（Yale University ）的历史学士学位，以及斯坦福大学商学院 （ Stanford Graduate School of Business ）的工商管理硕士学位。
Daniel N. Swisher, Jr. was appointed our President and Chief Operating Officer as of January 2018. From December 2003 to December 2017 he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001 Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation from 1992 to 2001. He currently serves as Chairman of the board of directors of Cerus Corporation, a biomedical products company focused on the field of blood transfusion safety, and as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating therapeutics to address metabolic and other serious medical conditions. Mr. Swisher received a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.- Daniel N. Swisher, Jr.，2004年1月以来，他担任我们呢首席执行官以及我们董事会成员。2004年1月以来，他也担任我们呢总裁。从2001年12月到2003年12月，他担任我们的首席商务官和首席财务官。从1992年6月到2001年9月，他担任各种管理职务，包括ALZA Corporation的高级副总裁负责销售和市场营销。他担任Cerus Corporation（生物制药公司）的董事会非执行主席。他持有耶鲁大学（Yale University ）的历史学士学位，以及斯坦福大学商学院 （ Stanford Graduate School of Business ）的工商管理硕士学位。
- Daniel N. Swisher, Jr. was appointed our President and Chief Operating Officer as of January 2018. From December 2003 to December 2017 he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001 Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation from 1992 to 2001. He currently serves as Chairman of the board of directors of Cerus Corporation, a biomedical products company focused on the field of blood transfusion safety, and as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating therapeutics to address metabolic and other serious medical conditions. Mr. Swisher received a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
- Matthew K. Fust
Matthew K. Fust，从2009年1月至2013年10月，他曾是奥尼克斯制药公司（Onyx Pharmaceuticals，生物制药公司）的执行副总裁和首席财务官。在加入Onyx之前，他曾是Jazz Pharmaceuticals, Inc.（生物制药公司）的执行副总裁和首席财务官。2003年5月他加入该公司。从2002年5月到2003年5月，他曾是Perlegen Sciences, Inc.（生物技术公司）的首席财务官。从1996年6月到1996年1月，他曾是ALZA Corporation的财务总监然后担任首席财务官。此外，他是MacroGenics, Inc.（生物制药公司）和 Ultragenyx Pharmaceutical Inc.（生物制药公司）的董事会成员。他持有明尼苏达大学（ the University of Minnesota）的会计学士学位，以及斯坦福大学商学院 （ Stanford Graduate School of Business ）的工商管理硕士学位。
Matthew K. Fust,is a board member and advisor to life sciences companies. He has served as a member of the Board since March 2014. Mr. Fust has served on the board of directors of Dermira, Inc. since April 2014 MacroGenics, Inc. since March 2014 and Ultragenyx Pharmaceutical, Inc. since January 2014. Mr. Fust was previously Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from January 2009 through its acquisition by Amgen in October 2013. Mr. Fust continued as an employee of Amgen until January 2014. From May 2003 to December 2008 Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company. From 2002 to 2003 Mr. Fust served as Chief Financial Officer at Perlegen Sciences, a biopharmaceutical company. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, a pharmaceutical company, where he was an executive from 1996 until 2002. From 1991 until 1996 Mr. Fust was a manager in the healthcare strategy practice at Andersen Consulting. Mr. Fust received a B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.- Matthew K. Fust，从2009年1月至2013年10月，他曾是奥尼克斯制药公司（Onyx Pharmaceuticals，生物制药公司）的执行副总裁和首席财务官。在加入Onyx之前，他曾是Jazz Pharmaceuticals, Inc.（生物制药公司）的执行副总裁和首席财务官。2003年5月他加入该公司。从2002年5月到2003年5月，他曾是Perlegen Sciences, Inc.（生物技术公司）的首席财务官。从1996年6月到1996年1月，他曾是ALZA Corporation的财务总监然后担任首席财务官。此外，他是MacroGenics, Inc.（生物制药公司）和 Ultragenyx Pharmaceutical Inc.（生物制药公司）的董事会成员。他持有明尼苏达大学（ the University of Minnesota）的会计学士学位，以及斯坦福大学商学院 （ Stanford Graduate School of Business ）的工商管理硕士学位。
- Matthew K. Fust,is a board member and advisor to life sciences companies. He has served as a member of the Board since March 2014. Mr. Fust has served on the board of directors of Dermira, Inc. since April 2014 MacroGenics, Inc. since March 2014 and Ultragenyx Pharmaceutical, Inc. since January 2014. Mr. Fust was previously Executive Vice President and Chief Financial Officer of Onyx Pharmaceuticals, Inc., a biopharmaceutical company, from January 2009 through its acquisition by Amgen in October 2013. Mr. Fust continued as an employee of Amgen until January 2014. From May 2003 to December 2008 Mr. Fust served as Chief Financial Officer at Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company. From 2002 to 2003 Mr. Fust served as Chief Financial Officer at Perlegen Sciences, a biopharmaceutical company. Previously, he was Senior Vice President and Chief Financial Officer at ALZA Corporation, a pharmaceutical company, where he was an executive from 1996 until 2002. From 1991 until 1996 Mr. Fust was a manager in the healthcare strategy practice at Andersen Consulting. Mr. Fust received a B.A. from the University of Minnesota and an M.B.A. from the Stanford Graduate School of Business.
- Homer L. Pearce
Homer L. Pearce, Ph.D.，从1979年到2006年3月，他担任Eli Lilly & Company 的各种职务，包括副总裁负责癌症研究和临床调查（1994年到2002年）和Lilly Research Laboratories的杰出研究员负责癌症研究（2002年到2006年3月）。他是美国癌症研究协会（ the American Association for Cancer Research）、美国化学学会（the American Chemical Society）和美国科学促进协会（the American Association for the Advancement of Science）的成员。他还担任德州农工大学（ Texas A&M University)的学士学位和哈佛大学（Harvard University）有机化学博士学位.
Homer L. Pearce served in various capacities at Eli Lilly & Company between 1979 and March 2006 including Vice President, Cancer Research and Clinical Investigation from 1994 to 2002 and Distinguished Research Fellow, Cancer Research, Lilly Research Laboratories from 2002 to March 2006. Dr. Pearce is a member of the American Association for Cancer Research, the American Chemical Society and the American Association for the Advancement of Science. Dr. Pearce holds a B.S. from Texas A&M University and a Ph.D. in Organic Chemistry from Harvard University.- Homer L. Pearce, Ph.D.，从1979年到2006年3月，他担任Eli Lilly & Company 的各种职务，包括副总裁负责癌症研究和临床调查（1994年到2002年）和Lilly Research Laboratories的杰出研究员负责癌症研究（2002年到2006年3月）。他是美国癌症研究协会（ the American Association for Cancer Research）、美国化学学会（the American Chemical Society）和美国科学促进协会（the American Association for the Advancement of Science）的成员。他还担任德州农工大学（ Texas A&M University)的学士学位和哈佛大学（Harvard University）有机化学博士学位.
- Homer L. Pearce served in various capacities at Eli Lilly & Company between 1979 and March 2006 including Vice President, Cancer Research and Clinical Investigation from 1994 to 2002 and Distinguished Research Fellow, Cancer Research, Lilly Research Laboratories from 2002 to March 2006. Dr. Pearce is a member of the American Association for Cancer Research, the American Chemical Society and the American Association for the Advancement of Science. Dr. Pearce holds a B.S. from Texas A&M University and a Ph.D. in Organic Chemistry from Harvard University.
- Dayton Misfeldt
Dayton Misfeldt，他是Bay City Capital LLC（风险资本公司）的投资合伙人从事生物制药的投资机会。在2000年5月加入Bay City Capital之前，他曾是Roth Capital Partners的副总裁。他曾担任其生物制药行业卖方分析师。他担任LifeScience Economics的项目经理。他目前在Interleukin Genetics, Inc.（基因检测医疗保健公司）的董事会任职。他持有圣地亚哥的加州大学（University of California）的经济学学士学位。
Dayton Misfeldt is an Investment Partner at Bay City Capital LLC, a venture capital firm, and focuses on biopharmaceutical investment opportunities. Prior to joining Bay City Capital in May 2000 Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. Mr. Misfeldt has also worked as a Project Manager at LifeScience Economics. Mr. Misfeldt currently serves on the board of directors of Interleukin Genetics, Inc., a genetic testing healthcare company. Mr. Misfeldt received a B.A. in Economics from the University of California, San Diego.- Dayton Misfeldt，他是Bay City Capital LLC（风险资本公司）的投资合伙人从事生物制药的投资机会。在2000年5月加入Bay City Capital之前，他曾是Roth Capital Partners的副总裁。他曾担任其生物制药行业卖方分析师。他担任LifeScience Economics的项目经理。他目前在Interleukin Genetics, Inc.（基因检测医疗保健公司）的董事会任职。他持有圣地亚哥的加州大学（University of California）的经济学学士学位。
- Dayton Misfeldt is an Investment Partner at Bay City Capital LLC, a venture capital firm, and focuses on biopharmaceutical investment opportunities. Prior to joining Bay City Capital in May 2000 Mr. Misfeldt was a Vice President at Roth Capital Partners where he worked as a sell-side analyst covering the biopharmaceutical industry. Mr. Misfeldt has also worked as a Project Manager at LifeScience Economics. Mr. Misfeldt currently serves on the board of directors of Interleukin Genetics, Inc., a genetic testing healthcare company. Mr. Misfeldt received a B.A. in Economics from the University of California, San Diego.
- Steven B. Ketchum
Steven B. Ketchum, Ph.D.，从2008年6月到2012年2月，他担任我们高级副总裁负责研发。2012年2月他担任 Amarin Corporation plc（生物制药公司）的总裁负责研发和高级副总裁并开始担任我们董事会执行职务。从2005年5月到2008年5月，他担任Reliant Pharmaceuticals, Inc.（医药公司，2007年被GlaxoSmithKline收购）的高级副总裁负责研发和医学事务。从2002年6月到2005年4月，他担任IntraBiotics Pharmaceuticals, Inc.的高级副总裁负责运营和法规事务。从1994年11月到2002年5月，他也担任ALZA Corporation的职务，最后他担任高级董事负责法规事务。他还担任伦敦大学学院（University College London，由 the Sandoz Institute for Medical Research资助）的药理学博士学位和斯坦福大学（Stanford University）的生物科学学士学位。
Steven B. Ketchum joined Amarin in February 2012 as Senior Vice President and President of Research and Development. He was named Chief Scientific Officer in January 2016. Dr. Ketchum has 20 years of experience in late-stage product development and clinical regulatory strategy. From 2008 to 2012 Dr. Ketchum served as Senior Vice President of Research and Development for Sunesis Pharmaceuticals, Inc. where he provided strategic direction for all facets of research and development, including clinical strategy and operations, regulatory affairs, and pharmaceutical development and has served on its board of directors since his departure. From 2005 to 2008 Dr. Ketchum served as Senior Vice President of Research and Development and Medical Affairs for Reliant Pharmaceuticals where he led development and support activities for Lovaza and other commercialized cardiovascular products. Prior to 2005 Dr. Ketchum was Senior Vice President of Operations and Regulatory Affairs at IntraBiotics Pharmaceuticals, Inc., and also held positions of increasing responsibility in regulatory affairs during his nearly eight-year tenure at ALZA Corporation, where he supported the development and commercialization of a number of products, including Concerta. Dr. Ketchum earned a Ph.D. in pharmacology from University College London and a B.S. in biological sciences from Stanford University.- Steven B. Ketchum, Ph.D.，从2008年6月到2012年2月，他担任我们高级副总裁负责研发。2012年2月他担任 Amarin Corporation plc（生物制药公司）的总裁负责研发和高级副总裁并开始担任我们董事会执行职务。从2005年5月到2008年5月，他担任Reliant Pharmaceuticals, Inc.（医药公司，2007年被GlaxoSmithKline收购）的高级副总裁负责研发和医学事务。从2002年6月到2005年4月，他担任IntraBiotics Pharmaceuticals, Inc.的高级副总裁负责运营和法规事务。从1994年11月到2002年5月，他也担任ALZA Corporation的职务，最后他担任高级董事负责法规事务。他还担任伦敦大学学院（University College London，由 the Sandoz Institute for Medical Research资助）的药理学博士学位和斯坦福大学（Stanford University）的生物科学学士学位。
- Steven B. Ketchum joined Amarin in February 2012 as Senior Vice President and President of Research and Development. He was named Chief Scientific Officer in January 2016. Dr. Ketchum has 20 years of experience in late-stage product development and clinical regulatory strategy. From 2008 to 2012 Dr. Ketchum served as Senior Vice President of Research and Development for Sunesis Pharmaceuticals, Inc. where he provided strategic direction for all facets of research and development, including clinical strategy and operations, regulatory affairs, and pharmaceutical development and has served on its board of directors since his departure. From 2005 to 2008 Dr. Ketchum served as Senior Vice President of Research and Development and Medical Affairs for Reliant Pharmaceuticals where he led development and support activities for Lovaza and other commercialized cardiovascular products. Prior to 2005 Dr. Ketchum was Senior Vice President of Operations and Regulatory Affairs at IntraBiotics Pharmaceuticals, Inc., and also held positions of increasing responsibility in regulatory affairs during his nearly eight-year tenure at ALZA Corporation, where he supported the development and commercialization of a number of products, including Concerta. Dr. Ketchum earned a Ph.D. in pharmacology from University College London and a B.S. in biological sciences from Stanford University.
- David C. Stump
David C. Stump ，他曾一直担任公司董事会成员（2010年6月以来）。他最近任职 Human Genome Sciences公司（从1999年11月到2012年12月）。他担任 Human Genome Sciences公司（一家生物制药公司）的研究和开发执行副总裁（从2007年5月到2007年12月），药物开发的执行副总裁（从2003年12月到2007年5月）,药物开发高级副总裁（从1999年11月到2003年12月）。此前，他曾担任过Genentech公司的数个职位，包括临床研究副总裁,并于1996年被任命为Genentech 的领导，负责心血管药物开发活动。他曾担任佛蒙特大学的医学和生物化学副教授。他目前担任 Sunesis Pharmaceuticals公司（上市医药公司）和 MacroGenics公司（上市的生物制药公司）的董事会成员。他也服务于厄勒姆学院的董事会。他获得了印第安纳大学的医学博士学位和厄尔罕姆学院 的学士学位。他完成了内科,血液学,肿瘤学（爱荷华州立大学董事会认证在所有三个领域）的住院实习。
David C. Stump, M.D. has been a Director since October 2015. From November 1999 to December 2012 Dr. Stump was with Human Genome Sciences, Inc., a biopharmaceutical company, as Executive Vice President, Research and Development from May 2007 to December 2012 Executive Vice President, Drug Development from December 2003 to May 2007 and Senior Vice President, Drug Development from November 1999 to December 2003. Prior to joining Human Genome Sciences, Dr. Stump held roles of increasing responsibility at Genentech, Inc., a biopharmaceutical company, from 1989 to 1999 including Vice President, Clinical Research and Genentech Fellow. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. Dr. Stump has served as a member of the boards of directors at Sunesis Pharmaceuticals, Inc. since June 2006 MacroGenics, Inc. since September 2013 and Portola Pharmaceuticals, Inc. since September 2015 each of which is a publicly held biopharmaceutical company. He also currently serves on the board of trustees of Earlham College. Dr. Stump previously served as a director at Dendreon Corporation, a biotechnology company, from June 2010 to June 2015. Dr. Stump holds an A.B. from Earlham College and an M.D. from Indiana University and completed his residency and fellowship training in internal medicine, hematology, oncology and biochemistry at the University of Iowa.- David C. Stump ，他曾一直担任公司董事会成员（2010年6月以来）。他最近任职 Human Genome Sciences公司（从1999年11月到2012年12月）。他担任 Human Genome Sciences公司（一家生物制药公司）的研究和开发执行副总裁（从2007年5月到2007年12月），药物开发的执行副总裁（从2003年12月到2007年5月）,药物开发高级副总裁（从1999年11月到2003年12月）。此前，他曾担任过Genentech公司的数个职位，包括临床研究副总裁,并于1996年被任命为Genentech 的领导，负责心血管药物开发活动。他曾担任佛蒙特大学的医学和生物化学副教授。他目前担任 Sunesis Pharmaceuticals公司（上市医药公司）和 MacroGenics公司（上市的生物制药公司）的董事会成员。他也服务于厄勒姆学院的董事会。他获得了印第安纳大学的医学博士学位和厄尔罕姆学院 的学士学位。他完成了内科,血液学,肿瘤学（爱荷华州立大学董事会认证在所有三个领域）的住院实习。
- David C. Stump, M.D. has been a Director since October 2015. From November 1999 to December 2012 Dr. Stump was with Human Genome Sciences, Inc., a biopharmaceutical company, as Executive Vice President, Research and Development from May 2007 to December 2012 Executive Vice President, Drug Development from December 2003 to May 2007 and Senior Vice President, Drug Development from November 1999 to December 2003. Prior to joining Human Genome Sciences, Dr. Stump held roles of increasing responsibility at Genentech, Inc., a biopharmaceutical company, from 1989 to 1999 including Vice President, Clinical Research and Genentech Fellow. Prior to joining Genentech, Dr. Stump was an Associate Professor of Medicine and Biochemistry at the University of Vermont. Dr. Stump has served as a member of the boards of directors at Sunesis Pharmaceuticals, Inc. since June 2006 MacroGenics, Inc. since September 2013 and Portola Pharmaceuticals, Inc. since September 2015 each of which is a publicly held biopharmaceutical company. He also currently serves on the board of trustees of Earlham College. Dr. Stump previously served as a director at Dendreon Corporation, a biotechnology company, from June 2010 to June 2015. Dr. Stump holds an A.B. from Earlham College and an M.D. from Indiana University and completed his residency and fellowship training in internal medicine, hematology, oncology and biochemistry at the University of Iowa.
- Geoffrey M. Parker
自2009年12以来，Geoffrey M. Parker 一直担任我们的董事。自2010年9月以来，他曾担任Anacor制药公司的高级副总裁兼首席财务官。自2009年12月起，开始在一个咨询公司任职。从2009年7月至2010年7月，任InteKrin Therapeutics公司首席商务官，一家生物技术公司，并曾担任Goldman, Sachs & Co投资银行部运营总监兼合伙人。从1997至2009年，他管理Goldman Sachs’ 西部地区医疗投资银行业务。 1995年至1997年，他任Feibusch & Co副总裁，这是在加利福尼亚州Larkspur一家风险投资公司。他获得达特茅斯学院在工程科学和经济学学士学位和斯坦福大学工商管理硕士学位。
Geoffrey M. Parker has been a director of Perrigo since November 2016. Since April 2017 Mr. Parker has served as Chief Financial Officer of Tricida, Inc., a biopharmaceutical company. Mr. Parker previously served as Chief Financial Officer of Anacor Pharmaceuticals, a biopharmaceutical company, from September 2010 to May 2015. From 1997 to 2009 Mr. Parker led the West Coast Healthcare Investment Banking practice at Goldman Sachs, where he advised leading companies in the biotechnology, life science tools and medical device industries. Mr. Parker has served as a member of the board of directors of ChemoCentryx since December 2009.- 自2009年12以来，Geoffrey M. Parker 一直担任我们的董事。自2010年9月以来，他曾担任Anacor制药公司的高级副总裁兼首席财务官。自2009年12月起，开始在一个咨询公司任职。从2009年7月至2010年7月，任InteKrin Therapeutics公司首席商务官，一家生物技术公司，并曾担任Goldman, Sachs & Co投资银行部运营总监兼合伙人。从1997至2009年，他管理Goldman Sachs’ 西部地区医疗投资银行业务。 1995年至1997年，他任Feibusch & Co副总裁，这是在加利福尼亚州Larkspur一家风险投资公司。他获得达特茅斯学院在工程科学和经济学学士学位和斯坦福大学工商管理硕士学位。
- Geoffrey M. Parker has been a director of Perrigo since November 2016. Since April 2017 Mr. Parker has served as Chief Financial Officer of Tricida, Inc., a biopharmaceutical company. Mr. Parker previously served as Chief Financial Officer of Anacor Pharmaceuticals, a biopharmaceutical company, from September 2010 to May 2015. From 1997 to 2009 Mr. Parker led the West Coast Healthcare Investment Banking practice at Goldman Sachs, where he advised leading companies in the biotechnology, life science tools and medical device industries. Mr. Parker has served as a member of the board of directors of ChemoCentryx since December 2009.
- Steve R. Carchedi
Steve R. Carchedi，从2012年到2013年，他担任Mallinckrodt Specialty Pharmaceuticals（Covidien plc的药品业务）的总裁负责商业运营。他在几个主要的跨国制药公司担任重要职务。此前，他担任General Electric GE Healthcare-MDx 的首席营销官负责领导GE的医学诊断业务全球营销。在加入GE Healthcare之前，他担任Endo Pharmaceuticals、Enzon Pharmaceuticals和McNeil Specialty Pharmaceuticals（ Johnson & Johnson、Eli Lilly & Company和Bristol Myers Squibb子公司）的商业领导职务。他持有西切斯特大学（the West Chester University）的学士学位，以及德雷塞尔大学（Drexel University）的工商管理硕士学位。他也在Bionumerik Pharmaceuticals, Inc.的董事会任职。
Steve R. Carchedi currently serves as the Chief Executive Officer and President of Apexian Pharmaceuticals, Inc., an oncology discovery and development company, a position he has held since October 2016. Mr. Carchedi previously served as the Chief Executive Officer and President of Cornerstone Pharmaceticals, Inc., an oncology discovery and development company, from 2014 to 2016 and as the Senior Vice President and President, Commercial Operations for Mallinckrodt Pharmaceuticals from 2012 to 2013. He served as Chief Marketing Officer for General Electric GE Healthcare-MDx where he was responsible for leading worldwide marketing for GE’s Medical Diagnostics business. Prior to joining GE Healthcare, Mr. Carchedi held senior commercial leadership positions at Endo Pharmaceuticals, Enzon Pharmaceuticals and McNeil Specialty Pharmaceuticals, a subsidiary of Johnson & Johnson, Eli Lilly & Company and Bristol Myers Squibb. Mr. Carchedi holds a Bachelor of Science in marketing from the West Chester University and a Masters in Business Administration in marketing from Drexel University.- Steve R. Carchedi，从2012年到2013年，他担任Mallinckrodt Specialty Pharmaceuticals（Covidien plc的药品业务）的总裁负责商业运营。他在几个主要的跨国制药公司担任重要职务。此前，他担任General Electric GE Healthcare-MDx 的首席营销官负责领导GE的医学诊断业务全球营销。在加入GE Healthcare之前，他担任Endo Pharmaceuticals、Enzon Pharmaceuticals和McNeil Specialty Pharmaceuticals（ Johnson & Johnson、Eli Lilly & Company和Bristol Myers Squibb子公司）的商业领导职务。他持有西切斯特大学（the West Chester University）的学士学位，以及德雷塞尔大学（Drexel University）的工商管理硕士学位。他也在Bionumerik Pharmaceuticals, Inc.的董事会任职。
- Steve R. Carchedi currently serves as the Chief Executive Officer and President of Apexian Pharmaceuticals, Inc., an oncology discovery and development company, a position he has held since October 2016. Mr. Carchedi previously served as the Chief Executive Officer and President of Cornerstone Pharmaceticals, Inc., an oncology discovery and development company, from 2014 to 2016 and as the Senior Vice President and President, Commercial Operations for Mallinckrodt Pharmaceuticals from 2012 to 2013. He served as Chief Marketing Officer for General Electric GE Healthcare-MDx where he was responsible for leading worldwide marketing for GE’s Medical Diagnostics business. Prior to joining GE Healthcare, Mr. Carchedi held senior commercial leadership positions at Endo Pharmaceuticals, Enzon Pharmaceuticals and McNeil Specialty Pharmaceuticals, a subsidiary of Johnson & Johnson, Eli Lilly & Company and Bristol Myers Squibb. Mr. Carchedi holds a Bachelor of Science in marketing from the West Chester University and a Masters in Business Administration in marketing from Drexel University.
高管简历
中英对照 | 中文 | 英文- Daniel N. Swisher, Jr.
Daniel N. Swisher, Jr.，2004年1月以来，他担任我们呢首席执行官以及我们董事会成员。2004年1月以来，他也担任我们呢总裁。从2001年12月到2003年12月，他担任我们的首席商务官和首席财务官。从1992年6月到2001年9月，他担任各种管理职务，包括ALZA Corporation的高级副总裁负责销售和市场营销。他担任Cerus Corporation（生物制药公司）的董事会非执行主席。他持有耶鲁大学（Yale University ）的历史学士学位，以及斯坦福大学商学院 （ Stanford Graduate School of Business ）的工商管理硕士学位。
Daniel N. Swisher, Jr. was appointed our President and Chief Operating Officer as of January 2018. From December 2003 to December 2017 he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001 Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation from 1992 to 2001. He currently serves as Chairman of the board of directors of Cerus Corporation, a biomedical products company focused on the field of blood transfusion safety, and as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating therapeutics to address metabolic and other serious medical conditions. Mr. Swisher received a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.- Daniel N. Swisher, Jr.，2004年1月以来，他担任我们呢首席执行官以及我们董事会成员。2004年1月以来，他也担任我们呢总裁。从2001年12月到2003年12月，他担任我们的首席商务官和首席财务官。从1992年6月到2001年9月，他担任各种管理职务，包括ALZA Corporation的高级副总裁负责销售和市场营销。他担任Cerus Corporation（生物制药公司）的董事会非执行主席。他持有耶鲁大学（Yale University ）的历史学士学位，以及斯坦福大学商学院 （ Stanford Graduate School of Business ）的工商管理硕士学位。
- Daniel N. Swisher, Jr. was appointed our President and Chief Operating Officer as of January 2018. From December 2003 to December 2017 he was Chief Executive Officer and a member of the board of directors of Sunesis Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel targeted cancer therapeutics in hematologic and solid tumor malignancies. He also served as Chief Business Officer and Chief Financial Officer of Sunesis from 2001 to 2003. Prior to 2001 Mr. Swisher served in various management roles, including Senior Vice President of Sales and Marketing, for ALZA Corporation from 1992 to 2001. He currently serves as Chairman of the board of directors of Cerus Corporation, a biomedical products company focused on the field of blood transfusion safety, and as a member of the board of directors of Corcept Therapeutics Inc., a pharmaceutical company focused on cortisol-modulating therapeutics to address metabolic and other serious medical conditions. Mr. Swisher received a B.A. from Yale University and an M.B.A. from the Stanford Graduate School of Business.
- Eric H. Bjerkholt
Eric H. Bjerkholt，从2007年2月到2007年1月，他担任我们高级副总裁负责公司发展和财务以及首席财务官。同时，他被提拔为执行副总裁负责公司的发展和财务以及首席财务官。从2004年1月到2007年1月，他担任我们的高级副总裁和首席财务官。从2002年1月到2004年1月，他担任 IntraBiotics Pharmaceuticals, Inc.（专注于严重的传染性疾病治疗的抗菌和抗真菌药物发展的制药公司）的高级副总裁和首席财务官。他是LifeSpring Nutrition, Inc.（私人营养食品公司）的联合创始人。从1999年5月到2002年3月，他多次担任其首席执行官、总裁和首席财务官。从1990年到1997年，他曾是J.P. Morgan & Co.的投资银行家。他是StemCells, Inc.（生物科技公司）的董事会成员。他获得奥斯陆大学（the University of Oslo）的经济学学位和哈佛商学院（Harvard Business School)的工商管理硕士学位。
Eric H. Bjerkholt has served on our board of directors since April 2015. Since April 2017 Mr. Bjerkholt has been employed as Chief Financial Officer at Aimmune Therapeutics, Inc. From 2004 until April 2017 Mr. Bjerkholt held various roles at Sunesis Pharmaceuticals, Inc., a biopharmaceutical company developing oncology therapeutics, including as Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From 2002 to 2004 he was Senior Vice President and Chief Financial Officer at IntraBiotics Pharmaceuticals, Inc., a biopharmaceutical company that was acquired by Ardea Biosciences, Inc. in 2006. Mr. Bjerkholt was a co-founder of LifeSpring Nutrition, Inc., a nutraceutical company, and from 1999 to 2002 served at various times as its Chief Executive Officer, President, and Chief Financial Officer. From 1990 to 1997 he also served as a vice president in the healthcare banking group at J.P. Morgan & Co. Incorporated, an international banking firm. Mr. Bjerkholt served as a member of the board of directors and as chair of the audit committee of StemCells, a biotech company, until November 2016. Mr. Bjerkholt holds a Cand. Oecon degree in Economics from the University of Oslo and an M.B.A. from Harvard Business School.- Eric H. Bjerkholt，从2007年2月到2007年1月，他担任我们高级副总裁负责公司发展和财务以及首席财务官。同时，他被提拔为执行副总裁负责公司的发展和财务以及首席财务官。从2004年1月到2007年1月，他担任我们的高级副总裁和首席财务官。从2002年1月到2004年1月，他担任 IntraBiotics Pharmaceuticals, Inc.（专注于严重的传染性疾病治疗的抗菌和抗真菌药物发展的制药公司）的高级副总裁和首席财务官。他是LifeSpring Nutrition, Inc.（私人营养食品公司）的联合创始人。从1999年5月到2002年3月，他多次担任其首席执行官、总裁和首席财务官。从1990年到1997年，他曾是J.P. Morgan & Co.的投资银行家。他是StemCells, Inc.（生物科技公司）的董事会成员。他获得奥斯陆大学（the University of Oslo）的经济学学位和哈佛商学院（Harvard Business School)的工商管理硕士学位。
- Eric H. Bjerkholt has served on our board of directors since April 2015. Since April 2017 Mr. Bjerkholt has been employed as Chief Financial Officer at Aimmune Therapeutics, Inc. From 2004 until April 2017 Mr. Bjerkholt held various roles at Sunesis Pharmaceuticals, Inc., a biopharmaceutical company developing oncology therapeutics, including as Executive Vice President, Corporate Development and Finance and Chief Financial Officer. From 2002 to 2004 he was Senior Vice President and Chief Financial Officer at IntraBiotics Pharmaceuticals, Inc., a biopharmaceutical company that was acquired by Ardea Biosciences, Inc. in 2006. Mr. Bjerkholt was a co-founder of LifeSpring Nutrition, Inc., a nutraceutical company, and from 1999 to 2002 served at various times as its Chief Executive Officer, President, and Chief Financial Officer. From 1990 to 1997 he also served as a vice president in the healthcare banking group at J.P. Morgan & Co. Incorporated, an international banking firm. Mr. Bjerkholt served as a member of the board of directors and as chair of the audit committee of StemCells, a biotech company, until November 2016. Mr. Bjerkholt holds a Cand. Oecon degree in Economics from the University of Oslo and an M.B.A. from Harvard Business School.